Company news

Telix Pharmaceuticals Limited news in 2025

Telix Pharmaceuticals Limited's news releases, calls and decks from 2025, newest first.

View company

Precision Medicine Portfolio Update

December 21, 2025

ProstACT Global Study Status

December 17, 2025

Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

December 10, 2025

1st Patient Dosed in ProstACT Global Randomized Tx Expansion

December 7, 2025

Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held

November 21, 2025

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

November 19, 2025

OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer

November 11, 2025

Telix to Participate in UBS and Jefferies Global Healthcare Conferences

November 5, 2025

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

October 22, 2025

TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

October 23, 2025

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

October 14, 2025

Telix Announces Record-Breaking Presence at EANM 2025

September 29, 2025

CMS Grants Transitional Pass-Through Status for Gozellix

September 22, 2025

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

September 9, 2025

Telix and FDA Agree Resubmission Pathway for Pixclara NDA

September 8, 2025

Telix Provides Regulatory Update on TLX250-CDx

August 27, 2025

Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference

August 26, 2025

Telix H1 2025 Results Announcement

August 20, 2025

Telix H1 2025 Results Presentation

August 20, 2025

Telix H1 2025 Appendix 4D and Interim Report

August 20, 2025

Historical Financials in USD and H12025 OPEX (Unaudited)

August 4, 2025

Telix H1 2025 Results: Investor Webcast Notification

July 29, 2025

Telix Reports US$204M Q2 Revenue, Up 63% YOY

July 22, 2025

Gozellix Receives Permanent HCPCS Code

July 9, 2025

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

June 23, 2025

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

June 20, 2025

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

June 19, 2025

Telix Investor Day Presentation

June 11, 2025

Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan

June 3, 2025

Telix to Host Investor Day in New York City on June 11, 2025

May 22, 2025

Telix at ANZSNM Annual Scientific Meeting 2025

May 19, 2025

Illuccix China Phase 3 Study Completes Enrolment

May 12, 2025

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7, 2025

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

April 28, 2025

Telix Provides Regulatory Update on TLX101-CDx

April 27, 2025

Telix Reports US$186M Q1 Revenue, Up 62% YOY

April 22, 2025

FDA Approves New Prostate Cancer Imaging Agent Gozellix

March 20, 2025

Telix Completes FAP-Targeting Theranostic Acquisition

March 11, 2025

FDA accepts BLA and grants priority review for Zircaix

February 25, 2025

Telix Announces Change in Reporting Currency to USD

February 24, 2025

2024 Full Year Results Presentation

February 20, 2025

2024 Full Year Results Announcement

February 20, 2025

Appendix 4E and 2024 Annual Report

February 20, 2025

Illuccix Approved in the United Kingdom

February 12, 2025

Telix Completes Acquisition of Tx Assets, Biologics Platform

January 30, 2025

Telix Completes Acquisition of RLS (USA) Inc

January 27, 2025

Illuccix Receives European Approval

January 16, 2025

Telix JP Morgan Healthcare Conference 2025 Presentation

January 13, 2025

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

January 13, 2025

Presentation to Accompany Biologics Platform Acquisition

January 12, 2025

Older news releases →

Calls in 2025

Decks in 2025